비만 치료에서 semaglutide의 효능 및 안전성에 대한 고찰

키워드

참고문헌 (49)

1. Korean Society for the Study of Obesity, "Clinical practice guidelines for obesity", pp.1~17 (2022)
2. "2021 obesity fact sheet"[URL]
3. Clinical practice guidelines for diabetes, "Korean Diabetes Association", 21~183 (2023)
4. Drucker DJ, "The incretin system : glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368(9548), pp.1696~1705 (2006)
5. Holst JJ, "Glucagonlike peptide 1 : a newly discovered gastrointestinal hormone", Gastroenterology, 107(6), pp.1848~1855 (1994)
6. Vilsbøll T, "Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients", Diabetes, 50(3), pp.609~613 (2001)
7. "FDA approves Novo Nordisk diabetes drug Ozempic" (2017)[URL]
8. "FDA approves new drug treatment for chronic weight management, first since 2014" (2021)[URL]
9. "Ozempic prefilled pen (semaglutide)"[URL]
10. "Wegovy prefilled pen (semaglutide)"[URL]
11. "FDA approves first oral GLP-1 treatment for type 2 diabetes" (2019)[URL]
12. "Rybelsus (semaglutide)"[URL]
13. Sorli C, "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes(SUSTAIN 1) : a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial", Lancet Diabetes Endocrinol, 5(4), pp.251~260 (2017)
14. Rodbard HW, "Semaglutide Added to Basal Insulin in Type 2 Diabetes(SUSTAIN 5) : A Randomized, Controlled Trial", J Clin Endocrinol Metab, 103(6), pp.2291~2301 (2018)
15. Zinman B, "Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes(SUSTAIN 9) : a randomised, placebo-controlled trial", Lancet Diabetes Endocrinol, 7(5), pp.356~367 (2019)
16. Ahmann AJ, "Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes(SUSTAIN 3) : A 56-week, open-label, randomized clinical trial", Diabetes Care, 41(2), pp.258~266 (2018)
17. Pratley RE, "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes(SUSTAIN 7) : a randomised, open-label, phase 3b trial", Lancet Diabetes Endocrinol, 6(4), pp.275~286 (2018)
18. Capehorn MS, "Efficacy and safety of once-weekly semaglutide 1. 0mg vs once-daily liraglutide 1. 2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes(SUSTAIN 10)", Diabetes Metab, 46(2), pp.100~109 (2020)
19. Lingvay I, "Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes(SUSTAIN 8) : a double-blind, phase 3b, randomised controlled trial", Lancet Diabetes Endocrinol, 7(11), pp.834~844 (2019)
20. Wilding JPH, "Once-weekly semaglutide in adults with overweight or obesity", N Engl J Med, 384(11), pp.989~1002 (2021)
21. Rubino D, "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity : The STEP 4 randomized clinical trial", JAMA, 325(14), pp.1414~1425 (2021)
22. Wadden TA, "Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity : The STEP 3 randomized clinical trial", JAMA, 325(14), pp.1403~1413 (2021)
23. Garvey WT, "Two-year effects of semaglutide in adults with overweight or obesity : the STEP 5 trial", Nat Med, 28(10), pp.2083~2091 (2022)
24. Weghuber D, "Once-weekly semaglutide in adolescents with obesity", N Engl J Med, 387(24), pp.2245~2257 (2022)
25. Rubino DM, "Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes : The STEP 8 randomized clinical trial", JAMA, 327(2), pp.138~150 (2022)
26. Frías JP, "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes", N Engl J Med, 385(6), pp.503~515 (2021)
27. McGowan BM, "Impact of BMI and comorbidities on efficacy of once-weekly semaglutide : Post hoc analyses of the STEP 1 randomized trial", Obesity(Silver Spring), 31(4), pp.990~928 (2023)
28. Wilding JPH, "Weight regain and cardiometabolic effects after withdrawal of semaglutide : The STEP 1 trial extension", Diabetes Obes Metab, 24(8), pp.1553~1564 (2022)
29. Aroda VR, "PIONEER 1 : Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes", Diabetes Care, 42(9), pp.1724~1732 (2019)
30. Mosenzon O, "Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment(PIONEER 5) : a placebo-controlled, randomised, phase 3a trial", Lancet Diabetes Endocrinol, 7(7), pp.515~527 (2019)
31. Pratley R, "Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes(PIONEER 4) : a randomised, double-blind, phase 3a trial", Lancet, 394(10192), pp.39~50 (2019)
32. Rodbard HW, "Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin : The PIONEER 2 trial", Diabetes Care, 42(12), pp.2272~2281 (2019)
33. Yabe D, "Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes(PIONEER 10) : an open-label, randomised, active-controlled, phase 3a trial", Lancet Diabetes Endocrinol, 8(5), pp.392~406 (2020)
34. Yamada Y, "Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes(PIONEER 9) : a 52-week, phase 2", 3a, randomised, controlled trial, 2020, pp.8(5), 377~391
35. Zinman B, "Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes : The PIONEER 8 trial", Diabetes Care, 42(12), pp.2262~2271 (2019)
36. Knop FK, "Oral semaglutide 50 mg taken once per day in adults with overweight or obesity(OASIS 1) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 402(10403), pp.705~719 (2023)
37. American Diabetes Association, "Standards of care in diabetes – 2023", Diabetes Care, 46(Suppl. 1) (2023)
38. Blonde L, "American Association of Clinical Endocrinology clinical practice guideline : developing a diabetes mellitus comprehensive care plan – 2022 update", Endocr Pract, 28(10), pp.923~1049 (2022)
39. Korean Diabetes Association, "Clinical practice guidelines for diabetes", pp.89~ (2021)
40. Korean Diabetes Association, "Clinical practice guidelines for diabetes", pp.125~ (2023)
41. Grunvald E, "AGA clinical practice guideline on pharmacological interventions for adults with obesity", Gastroenterology, 163(5), pp.1198~1225 (2022)
42. "Ozempic this, Wegovy that: no matter what you call it, semaglutide is having a moment" (2023)[URL]
43. "CNN exclusive: prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients" (2023)[URL]
44. "Semaglutide injection" (2024)[URL]
45. Klein HE, "An ongoing crisis : semaglutide shortage raises dual concerns for obesity and diabetes treatment", American Journal of Managed Care (2023)
46. Leitner DR, "Obesity and type 2 diabetes : two diseases with a need for combined treatment strategies – EASO can lead the way", Obes Facts, 10(5), pp.483~492 (2017)
47. Lincoff AM, "Semaglutide and cardiovascular outcomes in obesity without diabetes", N Engl J Med, 389(24), pp.2221~2232 (2023)
48. "Novo Nordis", 2022
49. "Finally, a survey?...Is misuse of ‘obesity treatment’ okay?" (2023)[URL]

관련 논문AI추천